Heart Test Laboratories (HSCS) Short Interest Ratio & Short Volume

Short interest is the volume of Heart Test Laboratories shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 135,300 shares of HSCS short. 0.31% of Heart Test Laboratories' shares are currently sold short. Learn More on Heart Test Laboratories' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.31% of Heart Test Laboratories' floating shares are currently sold short.

Heart Test Laboratories saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 135,300 shares, a drop of 73.3% from the previous total of 506,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Heart Test Laboratories currently has issued a total of 65,560,000 shares. Some of Heart Test Laboratories' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Heart Test Laboratories currently has a public float of 43,720,000 shares.

0.31% of Heart Test Laboratories' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Heart Test Laboratories: Predictive Oncology Inc. (0.65%), First Wave BioPharma, Inc. (3.04%), Akari Therapeutics, Plc (0.16%), Trevena, Inc. (0.63%), Lixte Biotechnology Holdings, Inc. (0.97%), Xenetic Biosciences Inc (0.14%), Kazia Therapeutics Limited (1.59%), Vivos Therapeutics, Inc. (0.81%), AquaBounty Technologies, Inc. (4.27%), TRACON Pharmaceuticals, Inc. (32.67%),

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

Short selling HSCS is an investing strategy that aims to generate trading profit from Heart Test Laboratories as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Heart Test Laboratories occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HSCS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HSCS, twice per month. The most recent reporting period available is March, 31 2024.